A dispute over plaintiffs’ access to results of a Zantac (ranitidine) study sponsored by the US Food and Drug Administration illustrates how parties in multidistrict litigation are trying to get the agency to bolster their positions.
An attorney for FDA addressed an 8 April virtual discovery hearing in the ranitidine multidistrict litigation arguing that the information...